BOLERO-2

Background

Phase III, double-blind, placebo-controlled RCT. N=724 postmenopausal women with HR+ HER2- advanced breast cancer refractory to letrozole or anastrozole. Everolimus is an mTORC1 inhibitor; mTOR activation is a known endocrine-resistance mechanism.

Interventions and follow up

Arm A: Everolimus 10mg daily + exemestane 25mg daily
Arm B: Placebo + exemestane 25mg daily
Primary endpoint: Progression-free survival (PFS)
mFollow up: 18 months

Results

PFS (central review): 10.6 vs 4.1mo, HR 0.36, 95% CI 0.27–0.47, P<.001
PFS (local review): 11.0 vs 4.1mo, HR 0.35
OS: 31.0 vs 26.6mo, HR 0.89 — not significant

Adverse events

Mucosal: Stomatitis any grade 56% vs 12% (grade ≥3: 8%)
Pulmonary: Pneumonitis any grade 12% (grade ≥3: 3%)
Metabolic/hematologic: Grade ≥3 hyperglycemia 4%, anemia 6%, fatigue 4%
Tolerability: Dose reduction 41%; discontinuation 19%

Conclusions

Everolimus + exemestane significantly improved PFS vs exemestane alone in postmenopausal HR+ HER2- mBC refractory to NSAI — the first mTOR inhibitor combination approved in breast cancer. No OS benefit was demonstrated.

Key Limitations

No OS benefit — PFS doubling did not translate to survival, possibly due to post-progression therapies. Stomatitis and pneumonitis are frequent and clinically impactful; oral-care protocols required. Pre-CDK4/6 inhibitor era trial — NSAI-refractory population would now typically receive CDK4/6i + fulvestrant, making BOLERO-2 largely of historical relevance.

Clinical Context

Everolimus (Afinitor) + exemestane: FDA approved 2012, widely used pre-CDK4/6i era. With CDK4/6 inhibitors and PI3K/AKT targeted therapies, everolimus-based combinations are now largely later-line, still used in some CDK4/6i-pretreated patients after other targeted options are exhausted. ESMO-MCBS 3 (historical context).

References